Poor
Poorly Aligned
Patient Risk:
Moderate
Summary
The AI-generated claims regarding enteric coating dissolution, protective GI effects, and reduced GI risk are not supported by the provided FDA label sections. All evaluated claims are absent from label evidence. The accompanying analysis treats these as unsupported statements with suggested labeling actions.
Category Scores
Accurate Statements
Unsupported Statements
Enteric coating is designed to dissolve in the stomach's acidic environment.
absent_from_label
Enteric coating is designed to not break down until the pill reaches the intestines, where the pH levels are higher.
absent_from_label
This delayed release can significantly impact the way aspirin affects the digestive system.
absent_from_label
Enteric-coated aspirin is less likely to irritate the stomach lining.
absent_from_label
Enteric-coated aspirin is less likely to cause gastric bleeding.
absent_from_label
The enteric coating acts as a protective barrier, shielding the stomach lining from direct contact with aspirin.
absent_from_label
Studies have shown that enteric-coated aspirin has a reduced risk of gastrointestinal side effects, such as stomach ulcers and bleeding, compared to regular aspirin.
absent_from_label
This is because the delayed release of aspirin in the intestines reduces the concentration of active ingredient available to the stomach's lining.
absent_from_label
Enteric-coated aspirin can still have gastrointestinal effects, such as diarrhea, constipation, or gastrointestinal upset.
absent_from_label
These side effects are typically mild and less common compared to those experienced with regular aspirin.
absent_from_label
Contradictions
Important Omissions
No label discussion confirming enteric coating dissolution behavior or site of release; no pH-triggered-release data is provided in the cited sections.
Importance:
Moderate
No label statements about reduced GI irritation or reduced gastric bleeding with enteric-coated aspirin.
Importance:
Moderate
No label data supporting comparative GI safety between enteric-coated and regular aspirin.
Importance:
Moderate
No mechanism described in label for how delayed release would affect gastric exposure or safety implications.
Importance:
Moderate
No list of GI adverse events specific to enteric-coated formulations or frequency data.
Importance:
Moderate
No labeling guidance stating that enteric coating reduces or does not affect gastric bleeding risk.
Importance:
Moderate
No statement clarifying whether enteric coating is present on the product and its intended release site.
Importance:
Moderate
No labeling about the existence or non-existence of comparative data for GI safety vs regular aspirin.
Importance:
Moderate
No mechanism-based justification (pharmacokinetic rationale) for a claimed reduction in gastric exposure due to delayed release.
Importance:
Moderate
No explicit labeling instructions or cautions tied to enteric-coated formulations regarding GI effects.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Moderate
Multiple unsupported GI safety claims could mislead about enteric coating benefits; label lacks comparative data to substantiate these claims.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Low |
Recommendation
Poorly Aligned
Primary Issue
Enteric coating-related GI safety claims are not supported by the provided label sections.
Suggested Improvement
Limit reporting to label-supported information; remove enteric-coating GI benefit claims unless supported by labeled data; if such data exist, cite them explicitly in the labeling and ensure WARNINGS/ADVERSE REACTIONS address any true comparative risks.